"Goldman, like Allergan, has been going down, regardless of how the other companies are doing in its sector," said Cramer, who is the founder of TheStreet and the portfolio manager for Action Alerts PLUS.

"But that's pretty much where the similarities end," Cramer noted.

Cramer's team bought Goldman because it was a "best of breed" stock selling at a steep discount to the rest of its sector. Plus, Cramer said it has a "rock solid" balance sheet and recently reported its strongest return on equity in five years.

Allergan, on the other hand, lacks the same fundamental strength and was a "not-great" healthcare company when it got a takeover bid from Pfizer Inc. (PFE) . Cramer's AAP team sold its last remaining position in Allergan last week, he said.

Do you want more exclusive investing insight from Jim Cramer? Get 24/7 access to Jim's charitable-trust portfolio with a free trial to Action Alerts PLUS! You can also watch all of Jim Cramer's New York Stock Exchange live shows on YouTube.